
Prestige Consumer Healthcare Inc.: stock overview
Price
$46.19
November 13, 2026Market cap $2.2B
What Ploutos Investor adds for Prestige Consumer Healthcare
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from FY2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
Prestige Consumer Healthcare had revenue of $1.2B over the last 12 months and net income of $155M, a net margin of 13.3%. Revenue grew by 2.9% a year on average over the last 5 years. At $46.19 the shares trade at a P/E of 14.1, against a median of 16.3 over the last 4 fiscal years. It has net debt of $2.1B. It pays no dividend.
From its SEC filings (latest fiscal year to March 31, 2026) and the price of November 13, 2026.
Its SEC filings- Market cap
- $2.2B
- 47.37M shares
- P/E
- 14.1
- Today14.1Median16.3
- Revenue, 12 months
- $1.2B
- +2.9% a year over 5 years
- Net margin
- 13.3%
- FY2025: 17.5%, above 86% of its industry
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
-1.6% a year over 2 years
Fiscal years in figures
PBH's revenue, profit, cash flow and dividend with each year-end price, from FY2010 to FY2023, 14 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $3.6B
- $2.2B
- Enterprise value
- $4.2B
- P/E 3-year median: 17.4
- 14.1
- EV / EBIT
- 14.6
- EV / Revenue
- 3.6
- P/B 3-year median: 2.2
- 1.1
- FCF yield 3-year median: 6.6%
- 9.8%
- Earnings yield 3-year median: 5.7%
- 7.1%
Profitability
- Gross margin
- 52.5%
- Operating margin
- 25.0%
- Net margin 3-year median: 18.6%
- 13.3%
- ROIC
- 7.0%
- ROIC, 5-year average
- 7.1%
- ROE
- 8.3%
Growth
- Revenue, yearly change
- -4.3%
- EPS, yearly change
- -8.9%
- FCF, yearly change
- +1.3%
- Revenue, average a year
- +2.9%
- EPS, average a year
- +3.8%
The yearly change compares FY2026 with FY2025.
Balance sheet
- Cash
- $47M
- Total debt
- $2.1B
- Of which operating leases
- $25M
- Net debt
- $2.1B
- Net debt / EBITDA
- 6.4x
- Interest cover
- –
- Current ratio
- 2.92
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- 7.14%
- Total returned
- 7.14%
- Shares, yearly change
- -4.1%
Against its industry
Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).
Gross margin
54.7%
Above 64% of the 141 companies in its industry, and 73% of all.
Operating margin
28.4%
Above 91% of the 285 companies in its industry, and 91% of all.
Net margin
17.5%
Above 86% of the 302 companies in its industry, and 79% of all.
ROE
10.4%
Above 69% of the 267 companies in its industry, and 62% of all.
ROA
5.5%
Above 72% of the 313 companies in its industry, and 74% of all.
Revenue growth
-4.3%
Above 22% of the 292 companies in its industry, and 18% of all.
From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- Prestige Consumer Healthcare Inc.
- CIK
- 1295947
- Exchange
- NYSE
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Fiscal year ends
- March 31
- Latest annual report
- March 31, 2026
- Reporting currency
- USD
- Shares
- 47.37M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with PBH
- JNJJohnson & Johnson+0,00%Compare with PBH
- ABBVAbbVie+0,00%Compare with PBH
- UNHUnitedHealth+0,00%Compare with PBH
- MRKMerck & Company+0,00%Compare with PBH
- AMGNAmgen+0,00%Compare with PBH
- TMOThermo Fisher Scientific+0,00%Compare with PBH
- ABTAbbott Laboratories+0,00%Compare with PBH
The full analysis
What do Prestige Consumer Healthcare's filings show?
These are Prestige Consumer Healthcare's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is PBH's market cap?
Prestige Consumer Healthcare Inc.'s market cap is $2.2B, at a price of $46.19 on November 13, 2026 and 47.37M shares.
What is PBH's P/E?
PBH's P/E is 14.1, on earnings per share of $3.24 over the last 12 months. The median over the last 4 fiscal years was 16.3.
How much revenue does PBH have?
Prestige Consumer Healthcare had revenue of $1.2B over the last 12 months. Over the last 5 years it changed by +2.9% a year on average.
Does PBH pay a dividend?
No. Prestige Consumer Healthcare paid no regular dividend over the last 12 months.
Where do the figures come from?
From Prestige Consumer Healthcare Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.